Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Clinical trial NCT02236195 · COMPLETED
Trial details
- NCT number
- NCT02236195
- Sponsor
- Mirati Therapeutics Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2016-04-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.